NCT00828867已完成1 期
A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Investigational Study Drug in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Safety parameters, adverse events, absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram intervals, and ECG rhythm.
研究概览
简要总结
This is a first time in human (FTIH) study of single escalating doses of investigational study drug to investigate safety, tolerability, and pharmacokinetics in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •non-childbearling potential females
- •Body weight greater than or equal to 50 kg (110 lbs) for men and greater than or equal to 45 kg (99 lbs) for women. Body mass index (BMI) between 18.5-29.9 kg/m2 inclusive.
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- •QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block on Screening ECG
排除标准
- •The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- •A positive test for HIV antibody.
- •History of regular alcohol consumption within 6 months of the study defined as:
- •an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). A standard unit is defined as 10g ethanol which is equivalent to 100mL wine, 250mL full strength beer, 470mL light beer, 30mL spirits
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Pregnant females as determined by positive [serum or urine] human chorionic gonadotropin (hCG) test at screening or prior to dosing.
- •Lactating females.
- •Subjects who have asthma or a history of asthma within the past 6 months.
- •History of smoking or history of regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
- •Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pummelos, satsuma, ugli, tangerine, and tangelo, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication
研究组 & 干预措施
Cohort 1
Experimental
100mg
干预措施: 100 mg GSK investigational drug (Drug)
Cohort 2
Experimental
200mg
干预措施: 200 mg GSK investigational drug (Drug)
Cohort 3
Experimental
400mg
干预措施: 400 mg GSK investigational drug (Drug)
Cohort 4
Experimental
800mg
干预措施: 800 mg GSK investigational drug (Drug)
Cohort 5
Experimental
1500mg
干预措施: 1500 mg GSK investigational drug (Drug)
Cohort 6
Experimental
2000mg
干预措施: 2000 mg GSK investigational drug (Drug)
Cohort 7
Experimental
800mg with food
干预措施: 800mg fed GSK investigational drug (Drug)
Cohort 8
Experimental
3000mg
干预措施: 3000mg GSK investigational drug (Drug)
Cohort 9
Experimental
4000mg
干预措施: 4000mg GSK investigational drug (Drug)
结局指标
主要结局
Safety parameters, adverse events, absolute values and changes over time of hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram intervals, and ECG rhythm.
时间窗: Eighteen days
Pharmacokinetic parameters following single dose administration: area under the plasma concentration curve AUC 0 to inf, AUC 0 to t, AUC 0 to 24, maximum observed concentration , time to maximum observed concentration , terminal half life .
时间窗: Two days, Three days (3000mg and 4000mg only)
次要结局
- AUC 0 to inf and Cmax following single dose administration for the assessment of dose proportionality(Two days, Three days (3000mg and 4000mg only))
- Amount excreted of unchanged study drug and renal clearance(Two days, Three days (3000mg and 4000mg only))
- AUC 0 to inf, AUC 0 to t, AUC 0 to 24, Cmax, tmax and tlag if deemed appropriate with and without high fat calorie meal(Two days, Three days (3000mg and 4000mg only))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable AsthmaticsPulmonary Disease, Chronic ObstructiveNCT04585009GlaxoSmithKline56
终止
1 期
A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002NCT06162299Yisheng Biopharma (Singapore) Pte. Ltd.16
已完成
1 期
Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)HealthyNCT02443740Biogen32
已完成
1 期
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.HealthyPlaque PsoriasisNCT06143371Otsuka Pharmaceutical Development & Commercialization, Inc.80
已完成
1 期
A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult ParticipantsHealthy VolunteersNCT06212804Otsuka Pharmaceutical Development & Commercialization, Inc.54